CN Mobile Logo

Search form


Radiation Therapy Alone Can Be Used to Treat Rectal Cancer

Radiation Therapy Alone Can Be Used to Treat Rectal Cancer

Radiation therapy alone is an adequate treatment for
some patients with rectal cancer, according to a study published in a recent
issue of the International Journal of Radiation Oncology, Biology, Physics
(54:142-149, 2002).

The most common treatment for rectal cancer, surgery, is sometimes combined
with radiation therapy to improve outcome. This study is the first of long-term
local control and survival in patients treated with radiation therapy alone, and
the results suggest that this is a suitable treatment for patients who are not
candidates for surgery.

Study Data

Between 1986 and 1998, 63 patients were entered into the pilot study.
Eligibility criteria included T2-3, N0-1, M0 adenocarcinoma of the middle or
lower rectum involving less than two-thirds of the circumference. Radiation
therapy began with contact x-rays, followed by external-beam radiation therapy
with a concomitant boost. After a 4- to 6-week interval, an iridium implant
delivered a completion dose to the tumor. No chemotherapy was administered.

The median age of patients was 72 years. Of the 63 enrolled patients, 41 had
T2 and 22 had T3 tumors. The mean distance of the tumor from the anal verge was
3.6 cm. All patients completed treatment according to the protocol, with the
exception of seven who did not receive brachytherapy. With a median follow-up of
54 months, the primary local tumor control rate was 63%; after salvage surgery,
the ultimate pelvic control rate was 73% (46 of 63). The 5-year overall survival
rate was 64.4% , and for 42 patients aged less than 80 years, it was 79%, with
10 patients alive at 10 or more years.

Adverse Effects

No severe toxicity was seen, and although proctitis developed in most
patients, it did not require an interruption in treatment. Late rectal bleeding
occurred in 24 patients, but only one required a blood transfusion. Good
anorectal function was maintained in 92% of living patients. The T stage was a
strong prognostic factor, with a 5-year overall survival rate of 84% and 53% for
T2 and T3 lesions, respectively, in patients under age 80.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.